Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
455.06B
Market cap455.06B
Price-Earnings ratio
18.23
Price-Earnings ratio18.23
Dividend yield
2.69%
Dividend yield2.69%
Average volume
7.85M
Average volume7.85M
High today
$189.71
High today$189.71
Low today
$186.76
Low today$186.76
Open price
$187.25
Open price$187.25
Volume
8.79M
Volume8.79M
52 Week high
$194.48
52 Week high$194.48
52 Week low
$140.68
52 Week low$140.68

JNJ News

Nasdaq 8h
These 3 Dividend Stocks Yield More Than 5% and Have Payout Ratios Over 100%. Are Dividend Cuts Coming?

Key Points Investors can look at a company's payout ratio to help gauge whether its dividend is sustainable. In some industries, however, companies use adjust...

These 3 Dividend Stocks Yield More Than 5% and Have Payout Ratios Over 100%. Are Dividend Cuts Coming?
Simply Wall St 18h
J&J’s IMAAVY™ Head-to-Head Study Might Change the Case for Investing in JNJ

Johnson & Johnson recently announced plans to launch the first head-to-head study comparing its FcRn blocker IMAAVY™ with other agents in generalized myasthenia...

J&J’s IMAAVY™ Head-to-Head Study Might Change the Case for Investing in JNJ
Nasdaq 1d
Validea Detailed Fundamental Analysis - JNJ

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...

Validea Detailed Fundamental Analysis - JNJ

Analyst ratings

56%

of 27 ratings
Buy
55.6%
Hold
37%
Sell
7.4%

More JNJ News

Nasdaq 1d
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's ear...

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Simply Wall St 2d
Protagonist Therapeutics: Assessing Valuation After Breakthrough Phase 2b Results and Johnson & Johnson’s Phase 3 Launch

Protagonist Therapeutics (PTGX) drew investor attention after reporting strong Phase 2b results for its drug icotrokinra. This development led Johnson & Johnson...

Protagonist Therapeutics: Assessing Valuation After Breakthrough Phase 2b Results and Johnson & Johnson’s Phase 3 Launch
Nasdaq 2d
Guru Fundamental Report for JNJ

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Inves...

Guru Fundamental Report for JNJ
TipRanks 3d
Trump Trade: Texas sues Kenvue, J&J over Tylenol autism risk

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump...

TipRanks 3d
Johnson & Johnson to begin FcRn blockers study

Johnson & Johnson announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis, or gMG, whic...

Benzinga 4d
Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety

Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson (NYSE:JNJ) and Kenvue Inc (NYSE:KVUE), accusing the companies of misleading preg...

Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety
TipRanks 4d
Citi says headlines could push consumers to alternatives to Kenvue’s Tylenol

After Texas Attorney General Ken Paxton announced he has sued Johnson & Johnson (JNJ) and Kenvue (KVUE) for marketing Tylenol to pregnant mothers, Citi analyst...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.